Official partnership with SGS to advance menstrual blood diagnostics
We’re proud to share that our collaboration with SGS is now an official partnership, supporting the development and validation of our menstrual blood test and the broader exploration of menstrual blood as a diagnostic matrix.
Together with SGS as an independent quality and validation partner, we are strengthening the scientific and regulatory foundations behind our work. Their expertise in bioanalytical sciences, quality assurance and validation supports both the analytical and clinical side of what we are building, helping ensure that this new approach is developed with rigour, structure and long-term trust in mind.
Menstrual blood is a complex biological source that contains valuable information linked to hormonal, immune and metabolic processes. Our work focuses on systematically studying its potential, from routine biomarkers to exploratory research into areas such as inflammation, endometriosis, PCOS and fertility-related conditions.
While the potential is significant, establishing menstrual blood as a clinically relevant matrix requires strong evidence, reproducibility and carefully controlled processes. This partnership allows us to embed these principles early, supporting the responsible development of a new, non-invasive pathway for women’s health diagnostics.
It is an important step in building the scientific credibility, quality framework and trust needed to move menstrual blood testing forward.
💡 Read the full partnership announcement here:
New Partnership with Innovative start-up theblood to Advance Women’s Health Diagnostics | SGS
Published 12 February 2026
If you’d like to stay up to date with our latest studies, publications, and behind-the-scenes progress, follow our updates here in the App or sign up for our newsletter.
